# Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum

Pre-Conference III:
Auditing, Monitoring and Effective
Internal Investigations

# Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum

Pre-Conference III:
Auditing, Monitoring and Effective
Internal Investigations

Implementing a Compliance Monitoring Program

## Agenda

- Introductions
- Implementing a Compliance Monitoring Program
  - ✓ Understanding the differences between monitoring and auditing
  - ✓ Establishing an effective compliance monitoring program
  - ✓ Case Study: Use of monitoring tools
- Q & A

## **Presenters**

- Christopher Santarcangelo, Assistant Director of Corporate Compliance, Purdue Pharma L.P.
- Jonathan Williams, Associate Director, Healthcare Compliance Office, Genentech, Inc.
- Tracy Mastro, Director, Huron Consulting Group



## **Compliance Monitoring and Auditing**


- One of the seven key elements of an effective Corporate Compliance program (HHS Office of Inspector General)
- Facilitates the identification and mitigation of compliance risks and improvement of internal controls
- Should be used to:
  - Measure and benchmark a Compliance program's effectiveness and impact on business activities
  - Document Company's compliance with internal written controls

## **Compliance Monitoring and Auditing**

- May be used to test the execution and effectiveness of functions at the core of a Compliance program, such as:
  - Compliance training
  - Employee and vendor screening
  - Disciplinary actions
- Should be used to measure a Compliance program's progress in attaining higher levels of compliance as the program matures

## **Key Objectives of Monitoring and Auditing**

	Auditing	Monitoring
1. Purpose	<ul> <li>Retrospective</li> <li>Processes and procedures comply with laws, regulations, policies</li> </ul>	<ul> <li>Retrospective or prospective (live)</li> <li>Daily activities to assess achievement of objectives</li> </ul>
2. Scope/ Focus	Internal controls and processes related to general business standards/policies	<ul> <li>Activities and transactions related to specific function/process/dept</li> <li>Internal and external focus</li> </ul>
3. Activities	<ul> <li>Periodic, structured reviews</li> <li>Conducted by independent staff</li> </ul>	Validate/measure performance     Business units self-monitor
4. Frequency	<ul> <li>Determined by risk-based audit plan</li> <li>"Snapshot" in time</li> </ul>	<ul> <li>Determined by frequency of transactions</li> <li>Ongoing process</li> </ul>
5. Reporting	Formal audit report with findings and recommendations	Variance analysis, exception reporting, performance metrics





## **Establish Foundation**

- Tone from the Top
- Organization Structure
- Baseline
   Understanding of the
   Effectiveness of
   Internal Controls
- Additional Internal Controls Implemented (if necessary)

## Design and Execution

- Prioritize Compliance Risks
- Identify Relevant Operating Controls
- Identify Individuals Responsible for Monitoring
- Design and Implement Monitoring Procedures

## Assess and Report

- Prioritize and Report Results and Findings
  - Identify Correction
    Action(s) and FollowUp
- Assign Individuals Responsible for Corrective Action

## **Design and Execution**

- Monitoring should be based on:
  - A fundamental analysis of compliance and business risks, and
  - An understanding of how key controls may/may not manage or mitigate risks
- Monitoring procedures also should be based on a Company's unique compliance risk profile
  - Prioritization of risks helps identify which risks are meaningful enough to subject to compliance monitoring
  - Results of risk assessments will influence decisions regarding the type, timing, and extent of monitoring

**Assessing Compliance Risks** 

#### **Gap Analysis and Monitoring Plan**

Internal monitoring groups evaluate the level of risks for each process and establish the extent of the monitoring for each process



#### **Risk Identification**

Using SMEs identify key compliance risks or risk areas (events or issues that will impact outcome of company's objectives).

#### **Process Risk Prioritization**

Link risks and processes with an exercise that creates ownership by process owners and agreement with compliance groups



#### 2 Risk Ranking

Develop ranking methodology to provide an objective transparent quantification of potential harm from non-compliance

#### **Risk Stratification Matrix**


Develop a transparent method to rank the risk of a process and its relative relationship with compliance risks



4

#### Risk Assessment

Prioritize risks based on Inherent nature (i.e. impact and likelihood)



#### **Business Processes and Owners**

Identify business process and owner(s) that are exposed to each risk and the extent of their exposure

## Design and Execution (cont'd)

- Monitoring should reflect a Company's internal written controls and control structure
- Determine the key controls that are important in managing or mitigating identified compliance risks
  - -Key controls are those that are most important to monitor
  - A focus on key controls helps ensure that the Company devotes monitoring resources efficiently and where they will provide the most value

## Establishing a Monitoring Program Prioritizing Monitoring Resources

HCP Meals Clinical Research Speakers & Consultants **EXTERNAL DRIVERS** State Reporting **Submissions Gov't Price** Reporting Dissemination of **Continuing Medical** Scientific Education Information **INTERNAL DRIVERS** 

#### **External Drivers**

- CIA
- Regulatory
- Legal
- Enforcement Action
- Industry Standards
- Public Opinion
- Media/Press

#### **Internal Drivers**

- Organizational Structures
- Organizational Change
- Operational Exposure
  - Complexity
  - Automation
  - Committed Resources
  - Recent Changes
- Self-Assessment
- Historical Audit Results
- Technology Capabilities

Low

High

### **Design and Execution (cont'd)**

- Monitoring procedures should be developed to reflect a Company's unique risk profile. For example:
  - Older products may represent kickback issues
    - Not much clinical discussion with sales representatives
    - Services offered to customers could be used to influence prescribing (e.g., grants, promotional speaking)
  - New products may represent off-label promotion risks
    - Dosing
    - Product used in combination with other therapies

### Design and Execution (cont'd)

- There are different way to measure risk. For example:
  - Number of statutory/regulatory violations
    - Kickbacks (e.g., payments to HCPs, marketing the spread)
    - Off-Label activities (e.g., requests for off-label information)
  - Number of policy violations
    - Compliance issues with policies (e.g., promotional speaker programs)
    - Compliance issues with processes (e.g., state reporting requirements on Travel & Expense reports)

## **Assess and Report**

- Results of monitoring should either:
  - Confirm previously established expectations about the effectiveness of internal controls, or
  - Highlight identified deficiencies for possible corrective action
- Results should be compiled, analyzed and reported to appropriate personnel for information and/or action

# Establishing a Monitoring Program Effective Programs

- Properly designed and executed, effective monitoring programs:
  - Provide the right information to the right people (e.g., Compliance, business units) regarding effectiveness
    - Effectiveness defined through identification of criteria, measures, and metrics
  - Identify and communicate internal control deficiencies in a timely manner
  - Facilitate the correction of control deficiencies before they materially affect the achievement of a Company's objectives



## **Case Study Objectives**

- The objectives of the Case Study are to:
  - Provide examples of situations in which monitoring may be used, and
  - How monitoring tools are used to determine whether compliance issues exist


## **Case Study Scenario**


- Company X recently a new Oncology product launch in January 2008
  - The new product was approved for Lung cancer
  - -There are studies that show the product's potential effectiveness in Thoracic cancer, an off-label use
- The product's Brand Plan reflects that Company X has been using promotional speaker programs, Advisory Board meetings, and CME to inform physicians about its new product

## **Case Study: Monitoring Activities**

#### **Medical Communications**

- During the ongoing Medical Communications monitoring process, the Compliance unit discovered a spike in requests for off-label information for Product X in March of 2008
- Compliance looked at the monitoring data for requests coming in since January 2008 and identified the following trends





## Case Study: Monitoring Activities

## **Important Data Reference Points**

- Requests for off-label information
  - Dates of conferences/meetings
  - Trends in requests (e.g., by region, sales rep)
  - MSL activities
  - Other activities in region
  - Internal communications to sales force
- Advisory Board meetings
- Promotional Speaker programs
- Continuing Medical Education meetings

## **Case Study: Monitoring Activities**

## Sales Representative Ride-Along

- Inform Sales Rep and DM of ride-along
- Compliance monitor identified generically as being from "home office"
- Sales Rep behaviors monitored:
  - Conversations with DM
  - Interactions/discussions with physician(s), nurses and office staff
    - Discussions of grants, CME programs, sponsorships, other consulting opportunities
  - Comments made by physicians, nurses and/or office staff to sales rep
  - Use of reprints/other leave behind materials

## **Questions?**

### **Chris Santarcangelo**

203.588.4320

Chris.santarcangelo@pharma.com

## Jonathan Williams, Esq.

650.225.2386

Williams.jonathan@gene.com

## **Tracy Mastro**

202.585.6862

tmastro@huronconsultinggroup.com